CoChat

Effects of HIF-1 and HIF2 on Growth and Metabolism of Clear-Cell Renal Cell Carcinoma 786-0 Xenografts

Open access

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Abstract

In cultured clear-cell renal carcinoma (CCRCC) 786-0 cells transfected with HIF1 (HIF-1+), HIF-2 (HIF-2+), or empty vector (EV), no significant differences were observed in the growth rates in vitro, but when grown in vivo as xenografts HIF-2 significantly increased, and HIF-1 significantly decreased growth rates, compared to EV tumors. Factors associated with proliferation were increased and factors associated with cell death were decreased in HIF-2+ tumors. Metabolite profiles showed higher glucose and lower lactate and alanine levels in the HIF-2+ tumors whilst immunostaining demonstrated higher pyruvate dehydrogenase and lower pyruvate dehydrogenase kinase 1, compared to control tumors. Taken together, these results suggest that overexpression of HIF-2 in CCRCC 786-0 tumors regulated growth both by maintaining a low level of glycolysis and by allowing more mitochondrial metabolism and tolerance to ROS induced DNA damage. The growth profiles observed may be mediated by adaptive changes to a more oxidative phenotype.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2010/757908

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Features of CCRCC 786-0 tumors. (a–d) (x100 hpf) HIF-1α nuclear staining only (*P < .0001). (e–h) Differential HIF-2α nuclear staining (*P = .0004). (i) Clear-cell/sarcomatoid morphology (x40 hpf). (j) CD10+ staining typical of clear-cell RCC lineage (x100 hpf). (k) PTEN staining; positive staining only identified in murine fibroblasts (x100 hpf). (l) Akt staining, (m) Phospho-Ser473 Akt staining (highest in HIF-2+ tumors). *P values were calculated using an ANOVA test.
Figure 1 Features of CCRCC 786-0 tumors. (a–d) (x100 hpf) HIF-1α nuclear staining only (*P < .0001). (e–h) Differential HIF-2α nuclear staining (*P = .0004). (i) Clear-cell/sarcomatoid morphology (x40 hpf). (j) CD10+ staining typical of clear-cell RCC lineage (x100 hpf). (k) PTEN staining; positive staining only identified in murine fibroblasts (x100 hpf). (l) Akt staining, (m) Phospho-Ser473 Akt staining (highest in HIF-2+ tumors). *P values were calculated using an ANOVA test.CC BY · PubMed Central
Figure 2 (a) Growth curve kinetics of 786-0 CCRCC tumors in vivo. (b) Areas of tumor necrosis (%) *P > .1. *P values were calculated using an ANOVA test.
Figure 2 (a) Growth curve kinetics of 786-0 CCRCC tumors in vivo. (b) Areas of tumor necrosis (%) *P > .1. *P values were calculated using an ANOVA test.CC BY · PubMed Central
Figure 3 (x100 hpf). Growth and death markers in CCRCC 786-0 tumors. (a–d) Ki67 proliferation index (*P = .0006). (e–h) Cyclin D1 expression (*P = .001). (i–l) Apoptosis as measured by cleaved-caspase-3% index (*P = .0002). (m–p) BNIP3 expression (cytoplasm only) (*P = .0002). *P values were calculated using ANOVA test.
Figure 3 (x100 hpf). Growth and death markers in CCRCC 786-0 tumors. (a–d) Ki67 proliferation index (*P = .0006). (e–h) Cyclin D1 expression (*P = .001). (i–l) Apoptosis as measured by cleaved-caspase-3% index (*P = .0002). (m–p) BNIP3 expression (cytoplasm only) (*P = .0002). *P values were calculated using ANOVA test.CC BY · PubMed Central
Figure 4 Metabolism-related markers and metabolic profiles of CCRCC 786-0 tumors (x100 hpf). (a–d) GLUT-1 expression(*P = .01). (e–h) Hexokinase-II expression (*P = .0006). (i–l) LDH5 expression (*P = .004), (m) In vivo 1HMRS of 786-0 tumors. (n) High-resolution 1HMR Spectra of tumor extracts. *P values were calculated using an ANOVA test.
Figure 4 Metabolism-related markers and metabolic profiles of CCRCC 786-0 tumors (x100 hpf). (a–d) GLUT-1 expression(*P = .01). (e–h) Hexokinase-II expression (*P = .0006). (i–l) LDH5 expression (*P = .004), (m) In vivo 1HMRS of 786-0 tumors. (n) High-resolution 1HMR Spectra of tumor extracts. *P values were calculated using an ANOVA test.CC BY · PubMed Central
Figure 5 Markers of oxidative phosphorylation and mitochondrial load in CCRCC 786-0 tumors. (a–d) PDH expression (*P = .003). (e–h) PDK-1 expression (*P = .006). (i–l) TOM-20 (mitochondrial marker) expression (*P = .004). *P values were calculated using an ANOVA test.
Figure 5 Markers of oxidative phosphorylation and mitochondrial load in CCRCC 786-0 tumors. (a–d) PDH expression (*P = .003). (e–h) PDK-1 expression (*P = .006). (i–l) TOM-20 (mitochondrial marker) expression (*P = .004). *P values were calculated using an ANOVA test.CC BY · PubMed Central
Figure 6 Oxidative stress and DNA damage/repair in CCRCC 786-0 tumors. (a–d) 8-OH-Guanosine staining (oxidative stress marker) (*P = .001). (e–h) γH2A.X staining (double-stranded DNA damage) (*P = .004). (i–l) OGG1 expression (*P = .006). *P values were calculated using an ANOVA test.
Figure 6 Oxidative stress and DNA damage/repair in CCRCC 786-0 tumors. (a–d) 8-OH-Guanosine staining (oxidative stress marker) (*P = .001). (e–h) γH2A.X staining (double-stranded DNA damage) (*P = .004). (i–l) OGG1 expression (*P = .006). *P values were calculated using an ANOVA test.CC BY · PubMed Central
Figure 7 Markers of angiogenesis in CCRCC 786-0 tumors. (a–d) VEGF expression (*P = .003). (e–h) Murine CD31+ vessel staining (*P = .001). *P values were calculated using an ANOVA test.
Figure 7 Markers of angiogenesis in CCRCC 786-0 tumors. (a–d) VEGF expression (*P = .003). (e–h) Murine CD31+ vessel staining (*P = .001). *P values were calculated using an ANOVA test.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Research works printed but not linked: 2

  1. 1986, Journal of Magnetic Resonance, 66, 283
  2. 10.1002/(sici)1099-1492(199912)12:8<495::aid-nbm594>3.0.co;2-k · doi:10.1002/(sici)1099-1492(199912)12:8<495::aid-nbm594>3.0.co;2-k

Cited by

See all 105

Metadata

Authors
Biswas, S., Troy, H., Leek, R., Chung, Y.-L., Li, J.-L., Raval, R. R., Turley, H., Gatter, K., Pezzella, F., Griffiths, J. R., Stubbs, M., & Harris, A. L.
Affiliations
  • Freeman Hospital (GB)
  • Institute of Cancer Research (GB)
  • John Radcliffe Hospital (GB)
  • St George's, University of London (GB)
Corresponding author
Stubbs, Marion
Venue
Journal of Oncology
Published
2010
Volume
2010
Pages
1-14
ISSN
  • 1687-8450 (ISSN-L)
  • 1687-8469
OpenAlex
W1980522580
Cited by
89
References
46
Citations by year
2026: 2 · 2025: 3 · 2024: 2 · 2023: 4 · 2022: 8 · 2021: 4 · 2020: 7 · 2019: 5 · 2018: 5 · 2017: 7 · 2016: 6 · 2015: 6 · 2014: 7 · 2013: 6 · 2012: 7
FWCI
2.32
Type
journal article
Language
en
Open access
Locations
  • Journal of Oncology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PEARL (University of Plymouth) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • PEARL (University of Plymouth) (submittedVersion)
  • Newcastle University ePrints (Newcastle Univesity)
Funders
  • Li Ka Shing Foundation
  • Cancer Research UK (11562)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords
HIF-1α, HIF-2α, clear cell renal cell carcinoma, 786-0 cells, tumor growth, xenografts, glycolysis, mitochondrial metabolism, pyruvate dehydrogenase, pyruvate dehydrogenase kinase 1, reactive oxygen species, DNA damage tolerance, glucose metabolism, lactate, alanine, cell proliferation, cell death

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of HIF-1 and HIF2 on Growth and Metabolism of Clear-Cell Renal Cell Carcinoma 786-0 Xenografts. https://app.cochat.ai/papers/10.1155/2010/757908
The paper
Biswas, S., Troy, H., Leek, R., Chung, Y.-L., Li, J.-L., Raval, R. R., Turley, H., Gatter, K., Pezzella, F., Griffiths, J. R., Stubbs, M., & Harris, A. L. (2010). Effects of HIF-1 and HIF2 on Growth and Metabolism of Clear-Cell Renal Cell Carcinoma 786-0 Xenografts. Journal of Oncology. https://doi.org/10.1155/2010/757908

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.